Comprehensive genomic profiling from
a blood sample. Fast.
For patients with advanced solid tumour cancers
-
Before 1st Line Treatment
Get ahead of the challenges of tissue testing in advanced NSCLC by utilizing Guardant 360 to guide 1st line treatment decisions
-
At Progression
Get genomic information on over 70+ genes, including MSI across multiple solid tumors to help find cancer therapies and clinical trials.
Consistently High
Concordance with Tissue
Consistently High
Concordance with Tissue
-
Best-in-class detection
-
Extensively peer reviewed and published
-
Published analytical and clinical validation
-
Over 150 peer reviewed publications, more than 50 of which include associated clinical outcomes
Tissue has limitations beyound your control
- Treatment delays
- Patient burden
- Finite resource
- Practice/staff burden
Relying solely on tissue leads to undergenotyping
~ 1 in 2 NSCLC patiens are unable to get guideline-recommended
genes for NSCLC
Published data
Prospective study of 323 NSCLC patients found
Guardant360®
improved alteration detection
Order now
Learn more about how to order Guardant360®.
WHO ARE YOU?
Contact us
We are on hand to answer any questions you may have and always aim to reply within one business day. Please call or email our expert Client Service team.
Materials
Download materials to learn more about liquid biopsy, blood sample testing and Guardant360®.
Share
this website
Share this website with your healthcare professionals. Let them know liquid biopsy can help to choose the right treatment.
OR
Order
Guardant360®
Get started: our team will support you along the way. Please call or email our expert Client Service team.
Re-order
Guardant360® Kits
Send an email with the precise delivery address, contact phone number and number of kits or fill in the form.
Connect with our
Medical Team
Our medical team is ready to support you with any scientific or medical questions and help to understand our reports.